REDWOOD CITY, Calif.,
Oct. 27, 2014 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple
moderated poster presentations will be made at the American College
of Surgeons (ACS 2014) Clinical Congress October 26th to October 30th, 2014 at the Moscone
Center in San Francisco, CA.
The annual ACS meeting is one of the largest international meetings
of surgeons in the world. Pamela Palmer, M.D. Ph.D. will
present safety and efficacy data from the phase 3 trials evaluating
the Zalviso™ sufentanil sublingual tablet system for the treatment
of moderate-to-severe acute pain.
Details on the presentation times are as follows:
Wednesday, October 29, 2014 –
Poster Session PP20, Poster 51175 – Presentation time 11:30-1:00pm (local time)
Authors: Forrest G. Ringold, MD, Harold S. Minkowitz, MD, Tong-Joo Gan, MD, Keith
A. Aqua, MD and Pamela P. Palmer,
MD, PhD
Title: SUFENTANIL SUBLINGUAL TABLET SYSTEM EFFICACY AND
FUNCTIONALITY FOLLOWING MAJOR ABDOMINAL SURGERY IN YOUNG AND
ELDERLY ADULT PATIENTS
Wednesday, October 29, 2014 –
Poster Session PP20, Poster 51199 – Presentation time 11:30-1:00pm (local time)
Authors: Harold S. Minkowitz, MD, Tong-Joo Gan, MD and
Pamela P. Palmer, MD, PhD
Title: SUFENTANIL SUBLINGUAL TABLET SYSTEM ONSET OF ANALGESIA
COMPARED TO IV PATIENT-CONTROLLED ANALGESIA WITH MORPHINE - A PHASE
3 META-ANALYSIS
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
to improve the management of moderate-to-severe acute pain in adult
patients in the hospital setting by utilizing a high therapeutic
index opioid, through a non-invasive delivery route via a
pre-programmed, patient-controlled analgesia device. AcelRx has
announced positive results from each of the three completed Phase 3
clinical trials for Zalviso, and has submitted an NDA to the FDA
seeking approval for Zalviso in the treatment of moderate-to-severe
acute pain in adult patients in the hospital setting and on
July 25th, received a Complete
Response Letter from the FDA. AcelRx plans to initiate a Phase 3
clinical trial for ARX-04, a product candidate for the treatment of
moderate-to-severe acute pain in a medically supervised setting, by
the end of 2014. The Company has two additional pain treatment
product candidates, ARX-02 and ARX-03, which have completed Phase 2
clinical development. For additional information about AcelRx's
clinical programs, please visit www.acelrx.com.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-sublingual-sufentanil-data-presentations-at-the-american-college-of-surgeons-meeting-219197336.html
SOURCE AcelRx Pharmaceuticals, Inc.